phone Contact Us

Business Updates

Opharmic Reports Strong Progress in First Half of 2026 – Laying Strong Foundations for Multiple Exciting Milestones Ahead

Opharmic Reports Strong Progress in First Half of 2026 – Laying Strong Foundations for Multiple Exciting Milestones Ahead

Hong Kong, 30 June 2026

Opharmic Technology (HK) Limited today provided a summary of its achievements in the first half of 2026. The period was marked by intensive preparation and foundational work, setting the stage for multiple exciting developments to be gradually rolled out in the second half of the year.

The first half was anchored by the launch of the company’s 2026 annual theme “煥新 Glow”, which symbolizes rejuvenation, innovation, and bright future impact. This theme was powerfully embodied by the successful relocation to a new, state-of-the-art headquarters in Tsim Sha Tsui, complete with a grand opening ceremony. The modern facility is designed to accommodate 80–100% team expansion, features advanced lab infrastructure to support R&D activities and compliance requirements, and includes dedicated space for product realisation to enable clinical unit assembly and validation.

Key Highlights – H1 2026

  • Scientific Advisory Board Established: Formation of a high-caliber international SAB comprising five leading retinal specialists from the US, UK, Australia, Singapore, and Switzerland. Their expertise strengthens clinical strategy and regulatory preparedness.
  • Retinal Drug Delivery Programme (under MeticTouch® platform): The retinal drug delivery device has achieved readiness for First-in-Human (FIH) trials. Active engagements are underway with potential hospitals and Principal Investigators to support trial initiation.
  • Myopia Programme (under MeticStim® platform): Key advancements have been made in non-invasive myopia control and prevention, with breakthrough data expected to be released later in the year alongside accelerated product development efforts.
  • Corporate Development Preparation: Significant progress in building corporate development capabilities to support both clinical advancement and business development activities, including overseas operation expansion that is currently underway.
  • Partnership Momentum: Strong engagement and interest received from multiple potential partners across various programmes.

“The first half of 2026 has been a period of focused preparation, building a robust foundation for the exciting milestones we plan to roll out in the coming months,” said Dr. Langston Suen, CEO of Opharmic Technology. “With our new headquarters, strengthened advisory board, and pipeline readiness, we are well-positioned to deliver significant value to patients, partners, and stakeholders in the second half of the year.”

Looking ahead to H2 2026, Opharmic will focus on initiating FIH trials, announcing breakthrough data, advancing partnership discussions, and executing its corporate development strategies.

Author

Opharmic Technology